logo.png
Corbus Pharmaceuticals to Present at the Oppenheimer 29th Annual Healthcare Conference
11 mars 2019 08h35 HE | Corbus Pharmaceuticals Holdings, Inc.
- Presentation with live audio webcast on Tuesday, March 19, 2019 at 2:10 p.m. ET- Norwood, MA, March 11, 2019 (GLOBE NEWSWIRE) --  Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or...
CRBP-300-196.png
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in November
06 nov. 2018 08h00 HE | Corbus Pharmaceuticals Holdings, Inc.
– Jefferies 2018 London Healthcare Conference presentation with live audio webcast on Thursday, November 15 at 4:40 p.m. GMT – – 30th Annual Piper Jaffray Healthcare Conference presentation with...
CRBP-300-196.png
Corbus Pharmaceuticals Appoints Former Director of FDA Office of New Drugs John K. Jenkins, MD to Board of Directors
06 juin 2018 07h05 HE | Corbus Pharmaceuticals Holdings, Inc.
– Distinguished 25-year career serving at the U.S. Food and Drug Administration, including 15 years of senior leadership in CDER and OND – – Appointment brings regulatory experience to the Board of...
CRBP-300-196.png
Corbus Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference
24 mai 2018 08h00 HE | Corbus Pharmaceuticals Holdings, Inc.
- Live audio presentation and webcast on Wednesday, June 6th at 9:00 a.m. EDT - Norwood, MA, May 24, 2018 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or...
CRBP-300-196.png
Corbus Pharmaceuticals Adds Two Key Executives to Lead its Regulatory and CMC Operations
22 mai 2018 08h00 HE | Corbus Pharmaceuticals Holdings, Inc.
— Robert Discordia, Ph.D., named Vice President, Pharmaceutical Development & Manufacturing —    — Ross Lobell named Vice President, Regulatory Affairs — Norwood, MA, May 22, 2018 (GLOBE...
CRBP-300-196.png
Corbus Pharmaceuticals Announces Acceptance of Three Abstracts for Presentation at EULAR 2018 Annual Meeting
15 mai 2018 08h00 HE | Corbus Pharmaceuticals Holdings, Inc.
- Data from Phase 2 one-year open-label extension of lenabasum in systemic sclerosis and 6-month open-label extension data in dermatomyositis studies to be presented -  Norwood, MA, May 15,...
Corbus Pharmaceutica
Corbus Pharmaceuticals Reports 2018 First Quarter Financial Results and Provides Business Update
10 mai 2018 08h00 HE | Corbus Pharmaceuticals Holdings, Inc.
– Company continues to make consistent progress in the clinical development programs of lenabasum, in rare, chronic and serious inflammatory and fibrotic diseases – Norwood, MA, May 10, 2018 ...